Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Arrowhead Pharmaceuticals has moved to reassure Wall Street about its deal with Sarepta Therapeutics, telling investors that ...

Boston Scientific bumped up its financial forecasts for the remainder of this year, after reporting double-digit growth ...

Roche’s Flatiron Health is celebrating a milestone. Over the last year, the company has tripled the size of its international ...

The FDA is spotlighting a new medical device correction effort at Baxter over its large-volume Novum IQ infusion pump, ...

After a long, cash-strapped journey, French biotech Abivax has presented top-line data from the twin phase 3 trials of its lead ulcerative colitis candidate.  | After a long, cash-strapped journey, ...

Genentech has executed another round of layoffs, eliminating 87 positions at its headquarters in South San Francisco. | Genentech has executed another round of layoffs, eliminating 87 positions at its ...

Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new immunotherapy approach. | Dispatch Bio has unveiled with $216 million and ...

The FDA has begun accepting applications for a priority pathway designed to slas | The FDA has begun accepting applications for a priority pathway designed to slash review times to one to two months, ...

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...

Korean preclinical CRO CorestemChemon is expanding its offerings through a partnership with ATG Lifetech with the goal of ...

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb-girdle ...